Who
Robert N. Wilson
Director
Company insider
Files Form 4 as: Director, CalciMedica; Director, Charles Schwab; Director, Hess; Director, Madrigal Pharmaceuticals; Director, Vivus.
In numbers
- Trades disclosed
- 156
- Buys
- 17
- Sells
- 0
- Bought
- $3.0M
- Sold
- $0
- Companies
- 5
- Companies where not an officer
- 5
- First trade
- 3 Jan 2006
- Last trade
- 1 Oct 2026
- Last filed
- 5 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Oct 2026filed 5 Oct 2026 | CALC CalciMedicaoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 19 Aug 2026filed 21 Aug 2026 | CALC CalciMedicaoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,182,621 at $0.00 | filing |
| 19 Aug 2026filed 21 Aug 2026 | CALC CalciMedicaoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,182,621 at $0.00 | filing |
| 19 Aug 2026filed 21 Aug 2026 | CALC CalciMedicaoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 19 Aug 2026filed 21 Aug 2026 | CALC CalciMedicaoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,182,621 at $0.00 | filing |
| 19 Aug 2026filed 21 Aug 2026 | CALC CalciMedicaoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,182,621 at $0.00 | filing |
| 19 Aug 2026filed 21 Aug 2026 | CALC CalciMedicaoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 25 Jun 2026filed 29 Jun 2026 | CALC CalciMedicaBiotechnology | SEC FORM 4 Code A | $950K1,182,621 at $0.8033 | filing |
| 25 Jun 2026filed 29 Jun 2026 | CALC CalciMedicaBiotechnology | SEC FORM 4 Code A | $946K1,182,621 at $0.80 | filing |
| 18 Jul 2025filed 18 Jul 2025 | CALC CalciMedicaBiotechnology | SEC FORM 4 Bought | $13K4,500 at $2.87 | filing |
| 24 Jun 2025filed 26 Jun 2025 | CALC CalciMedicaoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 24 Jun 2025filed 26 Jun 2025 | CALC CalciMedicaoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,031 at $0.00 | filing |
| 24 Jun 2025filed 26 Jun 2025 | CALC CalciMedicaoption or derivative · Biotechnology | SEC FORM 4 Code A | —36,562 at $0.00 | filing |
| 24 Jun 2025filed 26 Jun 2025 | CALC CalciMedicaoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 1 Nov 2024filed 1 Nov 2024 | CALC CalciMedicaBiotechnology | SEC FORM 4 Bought | $200K53,333 at $3.75 | filing |
| 27 Aug 2024filed 28 Aug 2024 | CALC CalciMedicaoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 23 Aug 2024filed 26 Aug 2024 | CALC CalciMedicaBiotechnology | SEC FORM 4 Bought | $201K54,000 at $3.72 | filing |
| 28 Jun 2024filed 2 Jul 2024 | CALC CalciMedicaBiotechnology | SEC FORM 4 Bought | $180K51,278 at $3.52 | filing |
| 27 Jun 2024filed 1 Jul 2024 | CALC CalciMedicaBiotechnology | SEC FORM 4 Bought | $27K8,443 at $3.23 | filing |
| 28 Mar 2024filed 22 Apr 2024 | CALC CalciMedicaoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
News
Comparing Madrigal Pharmaceuticals (NASDAQ:MDGL) and Incyte (NASDAQ:INCY)MDGL · themarketsdaily.com · 20 Oct 2026Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)MDGL · manilatimes.net · 15 Oct 2026Madrigal Pharmaceuticals (NASDAQ:MDGL) & Coya Therapeutics (NASDAQ:COYA) Critical ContrastMDGL · themarketsdaily.com · 9 Oct 2026
0 headlines in the last 90 days name Robert N. Wilson; 3 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.